Topics

PolyProx Therapeutics Raises £3.4m Seed Financing to Validate Novel Class of Drugs to Treat Cancer

02:00 EDT 30 Apr 2019 | Businesswire
This article has expired, however you can still download the PDF.
Preview:
PolyProx Therapeutics, a new biotechnology company focused on the discovery and development of novel biopharmaceuticals for the treatment of cancer, today announced that it has raised £3.4m of seed capital. A spin out ...

Other Sources for this Article

Limewash, PR Agency
Sarah Brereton, Director
Tel: +44 (0)1223 813 560

NEXT ARTICLE

More From BioPortfolio on "PolyProx Therapeutics Raises £3.4m Seed Financing to Validate Novel Class of Drugs to Treat Cancer"

Quick Search

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Biotechnology Products
BioPortfolio lists over 550 biotechnology products - please open http://www.bioportfolio.com/channels?category_id=5 Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...